| The evolving role of medical therapy for chronic stable angina. | |
| | |
MedLine Citation:
|
PMID: 18611360 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The management of chronic stable angina has undergone considerable evolution over the past two decades. This article highlights the need for a comprehensive approach to management that includes carefully identifying cardiac risk factors, using therapeutic lifestyle interventions, aggressive, multifaceted medical therapy, and judiciously using myocardial revascularization. For patients whose ischemia cannot be optimally controlled with traditional anti-ischemic agents, a novel antianginal and anti-ischemic agent (ie, ranolazine) has promise in reducing refractory ischemia as add-on therapy. This article discusses the role of coronary artery bypass graft surgery and percutaneous coronary intervention (PCI) in managing chronic stable angina patients and the clinical implications of the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive drug Evaluation) trial. The combined use of a "focal" approach (PCI to treat the culprit stenosis) and a "systemic" approach (lifestyle intervention and aggressive pharmacotherapy) may afford the best event-free survival and clinical outcomes in patients with stable angina. |
| | |
Authors:
|
Freidy Eid; William E Boden |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Current cardiology reports Volume: 10 ISSN: 1534-3170 ISO Abbreviation: Curr Cardiol Rep Publication Date: 2008 Jul |
Date Detail:
|
Created Date: 2008-07-09 Completed Date: 2008-10-24 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100888969 Medline TA: Curr Cardiol Rep Country: United States |
Other Details:
|
Languages: eng Pagination: 263-71 Citation Subset: IM |
Affiliation:
|
Division of Cardiology, Buffalo General Hospital, SUNY at Buffalo School of Medicine, 100 High Street, Buffalo, NY 14203, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acetanilides
/
therapeutic use Angina Pectoris / drug therapy, surgery, therapy* Angioplasty, Transluminal, Percutaneous Coronary* Cardiovascular Agents / therapeutic use* Chronic Disease Combined Modality Therapy Coronary Artery Bypass* Disease-Free Survival Enzyme Inhibitors / therapeutic use Humans Piperazines / therapeutic use Platelet Aggregation Inhibitors / therapeutic use Risk Factors Risk Reduction Behavior* |
| Chemical | |
Reg. No./Substance:
|
0/Acetanilides; 0/Cardiovascular Agents; 0/Enzyme Inhibitors; 0/Piperazines; 0/Platelet Aggregation Inhibitors; 110445-25-5/ranolazine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Late adverse events after drug-eluting stent implantation.
Next Document: Optimal treatment of the diabetic patient with multivessel disease.